Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Fructose and lactose intolerance and malabsorption testing

A study published ahead of print in the Alimentary Pharmacology & Therapeutics examines the relationship between fructose and lactose intolerance with symptoms in functional gastrointestinal disorders

News image

The association of fructose and lactose intolerance and malabsorption with the symptoms of different functional gastrointestinal disorders remains unclear.

Professor Wilder-Smith and colleagues from Switzerland investigated the prevalence of fructose and lactose intolerance and malabsorption, and their association with clinical gastrointestinal as well as non-clinical gastrointestinal symptoms in functional gastrointestinal.

In addition, the team examined the outcome of dietary intervention.

The research team demonstrated fructose and lactose intolerance and malabsorption in 1372 functional gastrointestinal disorders patients in a single center using breath testing.

Results were correlated with clinical symptoms in different functional gastrointestinal disorders Rome III subgroups.

The doctors assessed that the effectiveness of a targeted saccharide-reduced diet after 68 weeks.

Intolerance prevalence across all functional gastrointestinal disorders was 60% to fructose, 51% to lactose, and 33% to both.

Malabsorption occurred in 45%, 32% and 16% respectively.

Adequate symptom relief was achieved in 80% of intolerant patients
Alimentary Pharmacology & Therapeutics

The research team found that there were no differences in intolerance or malabsorption prevalence between functional gastrointestinal disorders subgroups.

Functional gastrointestinal disorders symptoms correlated with symptoms evoked during testing, but not with malabsorption.

The team of doctors found that non-clinical gastrointestinal symptoms occurred more commonly in patients with intolerances.

Methane breath levels were not associated with constipation using several cut-off thresholds.

The research team noted that adequate symptom relief was achieved in 80% of intolerant patients, irrespective of malabsorption.

Fructose and lactose intolerances are common in functional gastrointestinal disorders and associated with increased non-clinical gastrointestinal symptoms, but not with specific functional gastrointestinal disorders subtypes.

Professor Wilder-Smith's team concluded, "Symptoms experienced during breath testing, but not malabsorption, correlate with functional gastrointestinal disorders symptoms.

"Effective symptom relief with dietary adaptation is not associated with malabsorption."

"Mechanisms relating to the generation of clinical gastrointestinal and non-clinical gastrointestinal symptoms due to lactose and fructose in functional gastrointestinal disorders need to be explored further."

Aliment Pharmacol Ther 2013: DOI: 10.1111/apt.12306
12 April 2013

Go to top of page Email this page Email this page to a colleague

 23 May 2015

Advanced search
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 22 May 2015 
Colonoscopy screening for colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 20 May 2015 
Refractory metastatic colorectal cancer
 20 May 2015 
Pancreatic neuroendocrine tumors
 20 May 2015 
Surveillance in long-segment Barrett's
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 19 May 2015 
Metabolic syndrome and Barrett's
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 18 May 2015 
ESPGHAN celiac guidelines
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 13 May 2015 
Hypnotherapy in IBS/IBD
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Response to sorafenib in hepatocellular carcinoma
 28 April 2015 
Risk factors of hepatocellular carcinoma
 28 April 2015 
Clinical outcomes after esophagectomy
 28 April 2015 
Alcohol drinking and risk of liver cirrhosis
 23 April 2015 
Gut microbiota modulation for alcoholic liver disease
 23 April 2015 
Moderate sodium restriction diet in cirrhosis
 23 April 2015 
Gastroesophageal junction disruption and obesity

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us